Stockreport

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data [Seeking Alpha]

Mind Medicine (MindMed) Inc. - Common Shares  (MNMD) 
PDF End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety [Read more]